MPM BioImpact’s CytomX Therapeutics CTMX Stock Holding History

MPM BioImpact’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-855,437	Closed	-$6.56M	–	12
2020 Q1	$6.56M	Hold	855,437	–	–	4.01%	8
2019 Q4	$7.11M	Buy	+855,437	New	+$5.77M	2.52%	10

Other funds holding CTMX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

MPM BioImpact's CTMX Position: Q2 2020 in Review

MPM BioImpact sold out of CytomX Therapeutics (CTMX) in Q2 2020, closing a stake of 855,437 shares — an estimated $6.56M sold.

MPM BioImpact first reported a position in CTMX in Q4 2019 and held it in 2 quarters. The position peaked at $7.11M in Q4 2019. 134 funds tracked by Wall St. Rank hold CTMX as of Q2 2020.

MPM BioImpact reported no remaining CytomX Therapeutics position as of Q2 2020 after selling out during the quarter.
MPM BioImpact sold 855,437 CytomX Therapeutics shares in Q2 2020, an estimated $6.56M.
MPM BioImpact first reported a position in CytomX Therapeutics in Q4 2019 and held it in 2 quarters.
MPM BioImpact's CytomX Therapeutics position peaked at $7.11M in Q4 2019.
134 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2020.

Based on MPM BioImpact's 13F filing for Q2 2020, filed 12 Aug 2020.